[go: up one dir, main page]

HUP0400475A3 - Pharmaceutical compositions containing combination of at least two compounds selected from an at1-receptor antagonist or an ace inhibitor or a hmg-co-a reductase inhibitor groups and use thereof - Google Patents

Pharmaceutical compositions containing combination of at least two compounds selected from an at1-receptor antagonist or an ace inhibitor or a hmg-co-a reductase inhibitor groups and use thereof

Info

Publication number
HUP0400475A3
HUP0400475A3 HU0400475A HUP0400475A HUP0400475A3 HU P0400475 A3 HUP0400475 A3 HU P0400475A3 HU 0400475 A HU0400475 A HU 0400475A HU P0400475 A HUP0400475 A HU P0400475A HU P0400475 A3 HUP0400475 A3 HU P0400475A3
Authority
HU
Hungary
Prior art keywords
hmg
pharmaceutical compositions
compositions containing
receptor antagonist
compounds selected
Prior art date
Application number
HU0400475A
Other languages
English (en)
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of HUP0400475A2 publication Critical patent/HUP0400475A2/hu
Publication of HUP0400475A3 publication Critical patent/HUP0400475A3/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/401—Proline; Derivatives thereof, e.g. captopril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Gynecology & Obstetrics (AREA)
  • Reproductive Health (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
HU0400475A 2000-04-12 2001-04-10 Pharmaceutical compositions containing combination of at least two compounds selected from an at1-receptor antagonist or an ace inhibitor or a hmg-co-a reductase inhibitor groups and use thereof HUP0400475A3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US19674300P 2000-04-12 2000-04-12
PCT/EP2001/004115 WO2001076573A2 (en) 2000-04-12 2001-04-10 Combination of at least two compounds selected from an at1-receptor antagonist or an ace inhibitor or a hmg-co-a reductase inhibitor groups

Publications (2)

Publication Number Publication Date
HUP0400475A2 HUP0400475A2 (hu) 2004-06-28
HUP0400475A3 true HUP0400475A3 (en) 2006-02-28

Family

ID=22726659

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0400475A HUP0400475A3 (en) 2000-04-12 2001-04-10 Pharmaceutical compositions containing combination of at least two compounds selected from an at1-receptor antagonist or an ace inhibitor or a hmg-co-a reductase inhibitor groups and use thereof

Country Status (20)

Country Link
US (2) US20040023840A1 (hu)
EP (1) EP1326604A2 (hu)
JP (1) JP2003530342A (hu)
KR (1) KR20020089433A (hu)
CN (2) CN1651087A (hu)
AR (1) AR032152A1 (hu)
AU (1) AU2001258323A1 (hu)
BR (1) BR0109966A (hu)
CA (1) CA2405793A1 (hu)
CZ (1) CZ20023381A3 (hu)
HU (1) HUP0400475A3 (hu)
IL (1) IL152079A0 (hu)
MX (1) MXPA02010090A (hu)
NO (1) NO20024921L (hu)
PE (1) PE20020229A1 (hu)
PL (1) PL365696A1 (hu)
RU (1) RU2298418C2 (hu)
SK (1) SK14642002A3 (hu)
WO (1) WO2001076573A2 (hu)
ZA (1) ZA200208203B (hu)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20120055730A (ko) 1999-08-30 2012-05-31 사노피-아벤티스 도이칠란트 게엠베하 레닌－안지오텐신 시스템 억제제를 포함하는 심혈관 사고 예방용 약제학적 조성물
US6242003B1 (en) * 2000-04-13 2001-06-05 Novartis Ag Organic compounds
IL153428A0 (en) * 2000-06-22 2003-07-06 Novartis Ag Solid valsartan pharmaceutical compositions
US20060127474A1 (en) 2001-04-11 2006-06-15 Oskar Kalb Pharmaceutical compositions comprising fluvastatin
US7504415B2 (en) 2001-04-19 2009-03-17 Kowa Co., Ltd. Therapeutic agent for glomerular disease
EP1438027A1 (en) 2001-10-25 2004-07-21 DepoMed, Inc. Methods of treatment using a gastric retained losartan dosage
EP1450793A2 (de) * 2001-11-23 2004-09-01 Solvay Pharmaceuticals GmbH Hypertoniebehandlung während der akuten phase des schlaganfalls
GB0209265D0 (en) 2002-04-23 2002-06-05 Novartis Ag Organic compounds
US7232828B2 (en) * 2002-08-10 2007-06-19 Bethesda Pharmaceuticals, Inc. PPAR Ligands that do not cause fluid retention, edema or congestive heart failure
ATE551056T1 (de) * 2002-12-27 2012-04-15 Takeda Pharmaceutical Mittel zur hemmung der körpergewichtszunahme
RS20050532A (en) 2003-01-14 2007-12-31 Arena Pharmaceuticals Inc., 1,2,3-trisubstituted aryl and heteroaryl derivatives as modulators of metabolism and the prpphylaxis and treatment of disorders related thereto such as diabetes and hyperglycemia
KR20050092119A (ko) * 2003-01-16 2005-09-20 베링거 인겔하임 인터내셔날 게엠베하 심혈관 질환, 심폐 질환, 폐 질환 또는 신장 질환을예방하거나 치료하기 위한 약제학적 배합물
DE10335027A1 (de) * 2003-07-31 2005-02-17 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verwendung von Angiotensin II Rezeptor Antagonisten
DE10301371A1 (de) * 2003-01-16 2004-08-05 Boehringer Ingelheim Pharma Gmbh & Co. Kg Pharmazeutische Kombination zur Prophylaxe oder Therapie von kardiovaskulären, kardiopulmonalen, pulmonalen oder renalen Krankheiten
AU2004233693B2 (en) * 2003-04-28 2007-07-19 Funahashi, Toru Adiponectin production enhancer
AU2004233691B2 (en) * 2003-04-28 2007-09-20 Sankyo Company, Limited Sugar intake-ability enhancer
EP2292620A3 (en) 2003-07-14 2011-06-22 Arena Pharmaceuticals, Inc. Fused-aryl and heteroaryl derivatives as modulators of metabolism and the prohylaxis and treatment of disorders related thereto
GB0322552D0 (en) 2003-09-26 2003-10-29 Astrazeneca Uk Ltd Therapeutic treatment
AU2008201290B2 (en) * 2003-09-26 2010-12-09 Astrazeneca Uk Limited Therapeutic treatment
MY147202A (en) * 2003-11-26 2012-11-14 Novartis Ag Compositions comprising organic compounds
CA2546793A1 (en) * 2003-12-16 2005-06-30 Novartis Ag Use of stating for the treatment of metabolic syndrome
ATE493973T1 (de) 2004-06-04 2011-01-15 Teva Pharma Irbesartan enthaltende pharmazeutische zusammensetzung
EP1806137A4 (en) 2004-10-29 2011-03-30 Kowa Co THERAPEUTIC AGENT FOR THE TREATMENT OF GLOMERULAR DISEASE
KR100582347B1 (ko) * 2004-12-30 2006-05-22 한미약품 주식회사 3-하이드록시-3-메틸글루타릴 조효소 ａ 환원효소 억제제및 고혈압 치료제의 복합제제 및 그의 제조방법
US20100028439A1 (en) * 2005-05-23 2010-02-04 Elan Pharma International Limited Nanoparticulate stabilized anti-hypertensive compositions
US8685952B2 (en) 2006-01-31 2014-04-01 Kowa Co., Ltd. Method for the treatment of diabetes
KR101436644B1 (ko) * 2006-01-31 2014-09-01 코와 가부시키가이샤 당뇨병 치료제
FR2911279B1 (fr) * 2007-01-11 2009-03-06 Servier Lab Utilisation de l'ivabradine pour l'obtention de medicaments destines au traitement de la dysfonction endotheliale
GB0715628D0 (en) * 2007-08-10 2007-09-19 Generics Uk Ltd Solid valsartan composition
RU2393857C2 (ru) * 2008-05-12 2010-07-10 Государственное образовательное учреждение высшего профессионального образования Читинская государственная медицинская академия Федерального агентства по здравоохранению и социальному развитию Лекарственное средство, оказывающее противосудорожное и антигипоксическое действие
MX2013003184A (es) 2010-09-22 2013-06-07 Arena Pharm Inc Moduladores del receptor gpr119 y el tratamiento de transtornos relacionados con el mismo.
RU2505297C1 (ru) * 2012-11-21 2014-01-27 Общество с ограниченной ответственностью "Научно-производственное объединение "Фарматрон" (НПО "Фарматрон") Средство для медикаментозной коррекции нарушений нитроксидергической системы
ES2637276T3 (es) * 2013-05-13 2017-10-11 Macro Plastics, Inc. Contenedor de envío que comprende un cierre de seguridad
BR102013028883A2 (pt) * 2013-11-08 2015-10-06 Hypermarcas S A forma farmacêutica oral para a prevenção de doenças vasculares, comprimido como forma farmacêutica e cápsula gelatinosa como forma farmacêutica
MD4412C1 (ro) * 2014-08-29 2016-11-30 Алёна ДУРНЯ Utilizare a acidului 4-({2-butil-5-[2-carboxi-2-(tiofen-2-ilmetil)et-1-en-1-il] -1H-imidazol-1-il}metil) benzoic pentru ameliorarea elasticităţii vasculare în profilaxia complicaţiilor de geneză hipertensivă
EP4445956A3 (en) 2015-01-06 2024-12-04 Arena Pharmaceuticals, Inc. Compound for use in treating conditions related to the s1p1 receptor
HUE060476T2 (hu) 2015-06-22 2023-03-28 Arena Pharm Inc (R)-2-(7-(4-ciklopentil-3-(trifluormetil)benziloxi)-1,2,3,4- tetrahidrociklopenta[B]indol-3-il)ecetsav kristályos L-arginin-sója S1P1 receptorral kapcsolatos rendellenességek esetén való alkalmazásra
CA3053418A1 (en) 2017-02-16 2018-08-23 Arena Pharmaceuticals, Inc. Compounds and methods for treatment of primary biliary cholangitis
EA034975B1 (ru) * 2018-03-13 2020-04-13 Владимир Александрович Горшков-Кантакузен Способ лечения лабильной и пароксизмальной гипертензии
CN112601516A (zh) 2018-06-06 2021-04-02 艾尼纳制药公司 治疗与s1p1受体相关的病况的方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5981470A (en) * 1994-06-07 1999-11-09 The University Of Birmingham Uterine fibroid treatment
CA2214143A1 (en) * 1995-04-07 1996-10-10 Marc De Gasparo Combination compositions containing benazepril or benazeprilat and valsartan
AU716519B2 (en) * 1995-06-30 2000-02-24 Laboratoires Merck Sharp & Dohme - Chibret Snc Method of treating renal disease using an ace inhibitor and an A II antagonist
IL126319A0 (en) * 1996-03-29 1999-05-09 Smithkline Beecham Corp Eprosartan dihydrate and a process for its production and formulation
ES2232873T3 (es) * 1996-07-15 2005-06-01 Sankyo Company Limited Composiciones farmaceuticas que comprenden el cs-866 y otros agentes que mejoran la resistencia a la insulina y su uso para el tratamiento de la arterosclerosis y el xantoma.

Also Published As

Publication number Publication date
CA2405793A1 (en) 2001-10-18
HUP0400475A2 (hu) 2004-06-28
PE20020229A1 (es) 2002-04-11
PL365696A1 (en) 2005-01-10
SK14642002A3 (sk) 2003-05-02
CN1440283A (zh) 2003-09-03
WO2001076573A3 (en) 2003-04-17
EP1326604A2 (en) 2003-07-16
NO20024921L (no) 2002-11-07
RU2298418C2 (ru) 2007-05-10
CN1651087A (zh) 2005-08-10
ZA200208203B (en) 2003-11-07
US20040023840A1 (en) 2004-02-05
BR0109966A (pt) 2003-08-05
AR032152A1 (es) 2003-10-29
MXPA02010090A (es) 2003-02-12
NO20024921D0 (no) 2002-10-11
AU2001258323A1 (en) 2001-10-23
US20070105894A1 (en) 2007-05-10
JP2003530342A (ja) 2003-10-14
CZ20023381A3 (cs) 2003-02-12
KR20020089433A (ko) 2002-11-29
IL152079A0 (en) 2003-05-29
WO2001076573A2 (en) 2001-10-18

Similar Documents

Publication Publication Date Title
HUP0400475A3 (en) Pharmaceutical compositions containing combination of at least two compounds selected from an at1-receptor antagonist or an ace inhibitor or a hmg-co-a reductase inhibitor groups and use thereof
HUP0302615A3 (en) Kinase inhibitor quinazoline derivatives and pharmaceutical compositions containing them and their use
HUP0303083A3 (en) Pharmaceutical compositions containing therapeutic combination of a cetp inhibitor and atorvastatin and their use
HUP0400206A3 (en) Imidazolidindion derivatives having metalloproteinase inhibitor effect a their use for preparation of pharmaceutical compositions and pharmaceutical compositions containing them
HUP0302412A3 (en) Betha-carboline derivatives useful as inhibitors of phosphodiesterase and pharmaceutical compositions containing the same
EE200200052A (et) HMG reduktaasi inhibiitorit sisaldavad farmatseutilised kompositsioonid
HUP0301005A3 (en) Pirrolotriazine inhibitors of kinases pharmaceutical compositions containing them and their use
HUP0302991A3 (en) Isoxazoles and their use as inhibitors of erk and pharmaceutical compositions containing the compounds
HUP0302485A3 (en) Arylmethylamine derivatives for use as tryptase inhibitors and pharmaceutical compositions containing them
HUP0302385A3 (en) New multicyclic compounds and their use and pharmaceutical compositions containing them
HUS1500068I1 (hu) Dezacetiláz inhibitor hatású hidroxamát származékok és ezeket tartalmazó gyógyszerkészítmények
HUP0400327A3 (en) Azole derivatives having metalloproteinase inhibitor effect pharmaceutical compositions containing them and their use
HUP0302922A3 (en) Imidazolo-5-yl-2-anilino-pyrimidines as agents for the inhibition of the cell proliferation and pharmaceutical compositions containing them
HUP0402370A3 (en) Pharmaceutical compositions containing cyclooxigenase-2 inhibitor and histone deacetylase inhibitor combination
HUP0204340A3 (en) Compositions for delivery of a cortisol antagonist and their use
HUP0200602A3 (en) Pharmaceutical compositions containing a combination of a 5-ht reuptake inhibitor and a h5-ht1b antagonist or partial agonist and their use
HUP0400328A3 (en) Metalloproteinase inhibitor azoles and pharmaceutical compositions containing them
HUP0302160A3 (en) Pharmaceutical compositions containing the combination of gaba agonists and sorbitol dehydrogenase inhibitors
HUP0401582A3 (en) Pharmaceutical compositions containing combination of nsaid and pde-4 inhibitors and their use
HUP0302068A3 (en) Use of cox-2 inhibitors for treating or preventing immunodeficiency and pharmaceutical compositions containing them
HUP0400654A3 (en) Substituted 8-arylquinoline phosphodiesterase 4 inhibitors and pharmaceutical compositions containing them
HUP0300332A3 (en) New combination of a betablocker and a cholesterol-lowering agent and pharmaceutical compositions containing them
WO2003057205A3 (de) KOMBINATION VON MTP INHIBITOREN ODER apoB-SEKRETIONS-INHIBITOREN MIT FIBRATEN ZUR VERWENDUNG ALS ARZNEIMITTEL
HRP20040909B1 (en) Pharmaceutical composition of a pde4 or a pde3/4 inhibitor and a histamine receptor antagonist
HUP0500078A3 (en) Pharmaceutical composition containing a combination of a pde inhibitor and a leukotriene receptor antagonist

Legal Events

Date Code Title Description
FD9A Lapse of provisional protection due to non-payment of fees